Rosen Law Firm has filed a class action lawsuit on behalf of investors in Nektar Therapeutics, alleging misleading statements regarding the REZOLVE-AA trial. Investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, may be eligible for compensation.
Related articles
Press ReleaseMay 25, 2026
FinVolution Group Announces New Share Repurchase Program of Up to US$150 million
May 25, 2026
Press ReleaseMay 25, 2026
TECO Signs Acquisition Agreement with Malaysia's Dynaciate, Targeting Exponential AIDC Revenue Growth Next Year
May 25, 2026
Press ReleaseMay 25, 2026
Cyient Semiconductors Announces Strategic Financing with Edelweiss at ~ USD 500 Mn. Equity Valuation
May 25, 2026
← Back to all articles
Generated by Olivia 6